AMRI expands manufacturing capabilities in India
US-based Albany Molecular Research (AMRI) is to expand its multipurpose pilot plant facilities in Aurangabad, India, which provide non-GMP manufacturing services up to 1,000-litre scale.
US-based Albany Molecular Research (AMRI) is to expand its multipurpose pilot plant facilities in Aurangabad, India, which provide non-GMP manufacturing services up to 1,000-litre scale.
In addition to being a stand-alone provider, the new facility will serve as an extension to AMRI's kilo lab capabilities in Hyderabad, which operate to 100 litres in scale. The plant was recently commissioned and its first production run is underway.
A proportion of plant production will be dedicated to making starting materials for AMRI's US manufacturing facilities, significantly diminishing that plant's reliance on external resource providers.
"We are pleased to offer another high value alternative to our customers seeking the cost benefit of doing business in Asia, but retaining the quality they expect from a US-based organisation," said chairman, ceo and president Dr Thomas E. D'Ambra. "Separately, we look forward to realising cost savings at our US manufacturing operations by becoming our own provider for some raw materials, eliminating third party costs in both money and lead time."